Janet Lynch Lambert, CEO, Alliance for Regenerative Medicine, Washington, D.C., comments on recent achievements and priorities for ARM in 2022. The past year has seen ARM expand in terms of partnerships with patient advocacy groups and research institutions and Ms Lambert additionally emphasizes the importance of ARM within the cell and gene therapy sector in terms influencing regulatory and reimbursement policies. This interview took place at Advanced Therapies Week 2022.

свернуть